
AI-driven platform for discovering transformative medicines in neuroinflammation and immunology.

Junction Bioscience, founded with a mission to revolutionize molecular discovery, leverages an autonomous AI scientist to uncover transformative medicines. The company's core focus lies at the intersection of neuroinflammation and immunology, aiming to develop best-in-class therapies for millions of patients. Their AI-driven hypothesis engine iterates on breakthrough chemistry from the lab, providing clarity and control over the molecular basis of disease.
Notable figures affiliated with Junction Bioscience include leading experts in AI and molecular biology, although specific names are not provided. The company has garnered attention for its innovative approach to drug discovery, positioning itself as a pioneer in the biotech industry. By integrating advanced AI with molecular science, Junction Bioscience has made significant strides in understanding and treating complex diseases, impacting both the scientific community and patient care.

Medium Biosciences
medium.bio

Tamarind Bio
tamarind.bio

Output Biosciences
outputbio.com
GEn1E Lifesciences
gen1e.com

1910
1910genetics.com

Parallel Bio
parallel.bio

CellChorus
cellchorus.com

AMPLY Discovery
amplydiscovery.com

Diffuse Bio
diffuse.bio

Biosim

Synkrino Biotherapeutics
synkrino.bio

Jura Bio
jurabio.com

Maven Bio
mavenbio.io

Lavo Life Sciences

Serinus Biosciences
serinus.bio
Companies similar to Junction Bioscience include Medium Biosciences, Tamarind Bio, Output Biosciences and GEn1E Lifesciences.
Junction Bioscience was founded in 2024.
Junction Bioscience's most recent funding round was for $500k (USD) in January 2024.
As of Jan 1, 2024, Junction Bioscience has raised a total of $500k (USD).
Junction Bioscience has 1 employee as of Mar 29, 2024.